Literature DB >> 16330496

Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain.

Scott G Summerfield1, Alexander J Stevens, Leanne Cutler, Maria del Carmen Osuna, Beverley Hammond, Sac-Pham Tang, Ann Hersey, David J Spalding, Phil Jeffrey.   

Abstract

This work examines the inter-relationship between the unbound drug fractions in blood and brain homogenate, passive membrane permeability, P-glycoprotein (Pgp) efflux ratio, and log octanol/water partition coefficients (cLogP) in determining the extent of central nervous system (CNS) penetration observed in vivo. The present results demonstrate that compounds often considered to be Pgp substrates in rodents (efflux ratio greater than 5 in multidrug resistant Madin-Darby canine kidney cells) with poor passive permeability may still exhibit reasonable CNS penetration in vivo; i.e., where the unbound fractions and nonspecific tissue binding act as a compensating force. In these instances, the efflux ratio and in vitro blood-brain partition ratio may be used to predict the in vivo blood-brain ratio. This relationship may be extended to account for the differences in CNS penetration observed in vivo between mdr1a/b wild type and knockout mice. In some instances, cross-species differences that might initially seem to be related to differing transporter expression can be rationalized from knowledge of unbound fractions alone. The results presented in this article suggest that the information exists to provide a coherent picture of the nature of CNS penetration in the drug discovery setting, allowing the focus to be shifted away from understanding CNS penetration toward the more important aspect of understanding CNS efficacy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16330496     DOI: 10.1124/jpet.105.092916

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

Review 1.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 2.  Positron emission tomography molecular imaging for drug development.

Authors:  Paul M Matthews; Eugenii A Rabiner; Jan Passchier; Roger N Gunn
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

Review 3.  Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.

Authors:  Yi Zheng; Xijing Chen; Leslie Z Benet
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

4.  Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs.

Authors:  Roger N Gunn; Scott G Summerfield; Cristian A Salinas; Kevin D Read; Qi Guo; Graham E Searle; Christine A Parker; Phil Jeffrey; Marc Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-25       Impact factor: 6.200

5.  Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiology.

Authors:  A K Bassil; C M Taylor; V J N Bolton; K M Gray; J D Brown; L Cutler; S G Summerfield; G Bruton; W J Winchester; K Lee; G J Sanger
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

Review 6.  Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  AAPS J       Date:  2013-06-20       Impact factor: 4.009

7.  Determination of the unbound fraction of R- and S-methadone in human brain.

Authors:  Karen M D Holm; Kristian Linnet
Journal:  Int J Legal Med       Date:  2016-04-07       Impact factor: 2.686

Review 8.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

9.  Lopinavir protein binding in HIV-1-infected pregnant women.

Authors:  F T Aweeka; A Stek; B M Best; C Hu; D Holland; A Hermes; S K Burchett; J Read; M Mirochnick; E V Capparelli
Journal:  HIV Med       Date:  2009-12-03       Impact factor: 3.180

10.  Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study.

Authors:  Bertold Renner; Josef Zacher; Asokumar Buvanendran; Gerrit Walter; Jochen Strauss; Kay Brune
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-01-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.